ArticleLeukemia2026

Measurable residual disease-guided, fixed-duration, potentially definitive therapy for standard risk newly diagnosed multiple myeloma.

Bhagirathbhai R Dholaria et al.PubMed ↗Publisher ↗

No numbers read from the abstract.